.Pharmacolibrary.Drugs.ATC.R.R03AK08

Information

Formoterol and beclometasone is a fixed-dose combination medicine consisting of formoterol, a long-acting beta-2 adrenergic agonist (LABA), and beclometasone dipropionate, an inhaled corticosteroid (ICS). This combination is primarily used for the treatment and management of asthma and chronic obstructive pulmonary disease (COPD). Both agents work synergistically to improve lung function and control symptoms. It is approved for therapeutic use in many regions and recommended in guidelines.

Pharmacokinetics

Estimated typical adult pharmacokinetic parameters for formoterol and beclometasone administered via inhalation, based on known data from individual monocomponents and similar combination products in healthy adults.

References

1. Kuna, P, et al., & Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. Pharmacology research & perspectives 10(4) e980–None. DOI:10.1002/prp2.980 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35733414

2. Chawes, BL, et al., & Bisgaard, H (2014). Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respiratory medicine 108(8) 1108–1116. DOI:10.1016/j.rmed.2014.05.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24993817

3. Luo, Z, et al., & Mariotti, F (2022). Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers. Pulmonary pharmacology & therapeutics 73-74 102129–None. DOI:10.1016/j.pupt.2022.102129 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35525480

Revisions

• 06/2025 initial generated model